Clinical Trials Directory

Trials / Completed

CompletedNCT00668343

Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
80 (estimated)
Sponsor
Tehran University of Medical Sciences · Academic / Other
Sex
All
Age
15 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Patient with relapsing remitting multiple sclerosis taking avonex are included in this double blind randomized control trial. Simvastatin is compared to placebo. end points of edss , total attack, new enhancing lesion and newt2 lesion in mri is evaluated as end point.

Conditions

Interventions

TypeNameDescription
DRUGsimvastatin40 mg/ day
DRUGplacebo80 mg /day

Timeline

Start date
2005-04-01
Primary completion
2008-03-01
Completion
2009-03-01
First posted
2008-04-29
Last updated
2010-07-30

Locations

1 site across 1 country: Iran

Source: ClinicalTrials.gov record NCT00668343. Inclusion in this directory is not an endorsement.

Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo (NCT00668343) · Clinical Trials Directory